Loyal Announces $45 Million Series B Financing led by Bain Capital Ventures for development of FDA-Approved Dog Lifespan Extension Drug.
Loyal Announces $45 Million Series B Financing led by Bain Capital Ventures for development of FDA-Approved Dog Lifespan Extension Drug.
03/21/24, 4:12 PM
Location
atlantaMoney raised
$45 million
Round Type
series b
Investors
Todd & Rahul’s Angel Fund, Quiet Capital, Collaborative Fund, Box Group, First Round Capital, Khosla Ventures, Valor Equity Partners, Bain Capital Ventures
Loyal, a biotech company specializing in longevity drugs for dogs, has secured $45 million in Series B funding led by Bain Capital Ventures. The funding will support the development and expected launch of FDA-approved dog lifespan extension drugs.
Company Info
Location
atlanta, georgia, united states
Additional Info
One of the first companies to offer end-to-end digital and AI-powered solutions spanning the entirety of the patient journey, Loyal is the preferred software solution for improved care utilization among the nation's leading health systems and hospitals. From selecting a provider best suited for them to closing the feedback loop on their experience, patients who engage with healthcare networks via our proprietary platform quite simply, tend to be more loyal. Learn how to streamline patients' navigation of your health system and network of clinical services at LoyalHealth.com.